Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST-001 in Relapsed/Refractory Small Cell Lung Cancer
NCT06922539Phase 1Recruiting
- Sponsor
- SciTech Development
- Start
- Dec 2025
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of fenretinide in small cell lung cancer (SCLC) (2 arms), sponsored by SciTech Development. Primary endpoint: Progression-Free Survival at 3 weeks. Started Dec 2025; status: recruiting.
02
Drugs
fenretinide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06922539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922539.